Abstract: The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M2 protein bearing viruses. These compounds are also useful as inhibitors of the replication factors of hepatitis virus type C (HVC). The invention also describes pharmaceutical compositions containing the compounds of the invention either alone or in combination admixed with a suitable and pharmaceutically acceptable carrier.

Abstract: Use of recombinant human lysozyme in the preparation of a medicament for controlling life-threatening diseases associated with abnormal cell proliferation and migration, such as cancer metastasis, by administering to a subject in need thereof therapeutically effective doses of recombinant human lysozyme to elicit said antiproliferative and antimetastatic effects.

Abstract: The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M2 protein bearing viruses. These compounds are also useful as inhibitors of the replication factors of hepatitis virus type C (HVC). The invention also describes pharmaceutical compositions containing the compounds of the invention either alone or in combination admixed with a suitable and pharmaceutically acceptable carrier.

Abstract: A pharmaceutical composition has a therapeutically effective amount of at least one of: a pharmaceutically active nasal peptide, its pharmaceutically acceptable salt and its peptidic fragment. The composition also contains an absorbefacient effective amount of THAM in a pharmaceutically acceptable, aqueous liquid diluent or carrier. The composition is provided in a convenient form for nasal administration. In one embodiment, the peptidic fragment may be selected physiologically active lymphokines and monokines, peptidic enzymes, proteic vaccines, peptidic toxoids and personalized proteins derived from genoma. In another embodiment, the peptidic fragment may be selected from the peptide hormones and hormone antagonists buserelin, desmopressin, vasopressin, angiotensin, felypressin, octreotide, somatropin, thyrotropin (TSH), somatostatin, gosereline, thryptorelin and insulin selected from the group consisting of cow and pig, synthetic and recombinant.

Abstract: The invention relates to the modification of recombinant human lysozyme from genetic engineering (rHLys) by reacting with activated polyethylene glycols (PEGs), which are partially binding or saturating with typical linkers one or more out of the six free amino groups of the five lysines (K) present in the rHLys chain. The resulting conjugate compounds of the invention (PEG-rHLys) and their addition salts, inhibit the abnormal cell proliferation and show remarkable antiproliferative and antimetastatic effects. The invention relates also to the use of the new compounds in the preparation of pharmaceutical compositions for treating a disease associated with abnormal cell proliferation, including cancer, by administering said conjugates to a subject in need thereof.

Abstract: A compound of general formula: [CH3O—(CH2—CH2—O)n—CH2—CH2]x—(NH)yLysozyme c. (Z)m wherein: y is the number of free amino groups of lysine molecules present in the molecule of lysozyme c; x is comprised between 1 and y; n is comprised between 5 and 1000; Z is a pharmaceutically acceptable acid; m is comprised between 1 and y.

Abstract: Use of modified lysozyme c or its pharmaceutically acceptable salts and its industrial production for the preparation of medicinal compositions, suitable for oral, parenteral and topical administration, for prophylaxis and therapy of diseases in mammals.

Abstract: The invention provides a pharmaceutical formulation comprising: (1) THAM, which is tris(hydroxymethyl)aminomethane, as a selective absorbefacient to enhance through the nasal mucosa-lined epithelium the absorption of substances of peptide nature; and (2) a therapeutically effective amount of active nasal peptide, its pharmaceutically acceptable salt or its peptidic fragment; in a pharmaceutically acceptable, aqueous liquid diluent or carrier, said formulation being in a form suitable for nasal administration.

Abstract: Use of modified lysozyme c or its pharmaceutically acceptable salts and its industrial production for the preparation of medicinal compositions, more particularly oral, parenteral and topical, for prophylaxis and therapy of some serious diseases in mammalians.